Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Pharmacogenetics and Pharmacogenomics: Overview01:29

Pharmacogenetics and Pharmacogenomics: Overview

Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes01:28

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The northern fulmar as a sentinel species for monitoring the environmental health impacts of plastic exposure.

Journal of toxicology and environmental health. Part B, Critical reviews·2026
Same author

Multiscale Modeling and Systems Biology in Microgravity Investigations.

Methods in molecular biology (Clifton, N.J.)·2026
Same author

Fusion genes in precision oncology: prostate cancer as a diagnostic case study.

Expert review of molecular diagnostics·2026
Same author

Transcriptomic Responses of Zebrafish Embryos to Environmentally Relevant, Low-Dose (2-Ethylhexyl) Phthalate Exposure at 96-120 hpf.

Genes·2026
Same author

A Th17 signature correlates with response to dual CTLA-4 and PD-1 blockade in metastatic renal cell carcinoma.

medRxiv : the preprint server for health sciences·2025
Same author

Targeted complement inhibition ameliorates the pathological and cognitive outcomes in repetitive mild closed head injury.

Signal transduction and targeted therapy·2025

Related Experiment Video

Updated: Jun 14, 2026

Infinium Assay for Large-scale SNP Genotyping Applications
13:33

Infinium Assay for Large-scale SNP Genotyping Applications

Published on: November 19, 2013

Advances in pharmacogenomics technologies.

C Ramana Bhasker1, Gary Hardiman

  • 1Department of Pediatrics, School of Medicine, University of California, San Diego, La Jolla, CA 92093, USA.

Pharmacogenomics
|March 31, 2010
PubMed
Summary
This summary is machine-generated.

Recent genomics technologies have advanced biomarker discovery and personalized medicine. These innovations improve patient care by enabling precise therapeutic monitoring and minimizing adverse drug reactions through pharmacogenetics.

More Related Videos

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry
05:53

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry

Published on: June 21, 2018

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies
13:24

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies

Published on: April 11, 2016

Related Experiment Videos

Last Updated: Jun 14, 2026

Infinium Assay for Large-scale SNP Genotyping Applications
13:33

Infinium Assay for Large-scale SNP Genotyping Applications

Published on: November 19, 2013

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry
05:53

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry

Published on: June 21, 2018

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies
13:24

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies

Published on: April 11, 2016

Area of Science:

  • Genomics and Bioinformatics
  • Pharmacogenetics
  • Molecular Biology

Background:

  • The last decade has witnessed significant technological advancements in genomics.
  • Improvements in DNA microarrays and massively parallel sequencing have transformed human genome interrogation.

Purpose of the Study:

  • To review the evolution and development of key genomics technologies over the past decade.
  • To highlight the impact of these technologies on biomarker discovery, therapeutic interventions, and patient care.

Main Methods:

  • Review of advancements in DNA microarray sensitivity and precision.
  • Analysis of the emergence and impact of massively parallel sequencing techniques.
  • Examination of the integration of pharmacogenetic approaches.

Main Results:

  • Genomic tools have accelerated biomarker discovery and identified novel therapeutic targets.
  • These technologies enable mechanistic studies of drug action and assessment of drug toxicity.
  • High-throughput screening for genetic variations aids in understanding interindividual drug responses.

Conclusions:

  • Genomics technologies have redefined human genome analysis and drug development.
  • Pharmacogenetic approaches, based on patient phenotype profiles, are crucial for minimizing adverse drug reactions.
  • The integration of genomics promises enhanced clinical treatments and improved patient care.